CA2374013A1 - Protein a based binding domains with desirable activities - Google Patents

Protein a based binding domains with desirable activities Download PDF

Info

Publication number
CA2374013A1
CA2374013A1 CA002374013A CA2374013A CA2374013A1 CA 2374013 A1 CA2374013 A1 CA 2374013A1 CA 002374013 A CA002374013 A CA 002374013A CA 2374013 A CA2374013 A CA 2374013A CA 2374013 A1 CA2374013 A1 CA 2374013A1
Authority
CA
Canada
Prior art keywords
spa
fab
variant
domain
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002374013A
Other languages
English (en)
French (fr)
Inventor
Gregg J. Silverman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2374013A1 publication Critical patent/CA2374013A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002374013A 1999-05-15 2000-05-15 Protein a based binding domains with desirable activities Abandoned CA2374013A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13438699P 1999-05-15 1999-05-15
US60/134,386 1999-05-15
PCT/US2000/013402 WO2000069457A1 (en) 1999-05-15 2000-05-15 Protein a based binding domains with desirable activities

Publications (1)

Publication Number Publication Date
CA2374013A1 true CA2374013A1 (en) 2000-11-23

Family

ID=22463140

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002374013A Abandoned CA2374013A1 (en) 1999-05-15 2000-05-15 Protein a based binding domains with desirable activities

Country Status (6)

Country Link
US (1) US20060205016A1 (enExample)
EP (2) EP1181052A4 (enExample)
JP (1) JP2002544237A (enExample)
AU (1) AU777005B2 (enExample)
CA (1) CA2374013A1 (enExample)
WO (1) WO2000069457A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425331B2 (en) 2002-04-10 2008-09-16 Protalex, Inc. Protein A methods of use
US7211258B2 (en) 2002-04-10 2007-05-01 Protalex, Inc. Protein A compositions and methods of use
CN101522278B (zh) 2006-09-29 2016-08-10 通用电气健康护理生物科学股份公司 用于抗体分离的包含来自金黄色葡萄球菌a蛋白的结构域c的层析配体
DK2102239T3 (da) * 2006-11-30 2012-05-29 Res Dev Foundation Forbedrede immunoglobulin-biblioteker
US7691608B2 (en) 2006-12-06 2010-04-06 Repligen Corporation Nucleic acids encoding recombinant protein A
US8592555B2 (en) * 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
WO2010035757A1 (ja) * 2008-09-25 2010-04-01 Jsr株式会社 アフィニティークロマトグラフィー用充填剤
SG195555A1 (en) 2008-12-24 2013-12-30 Emd Millipore Corp Caustic stable chromatography ligands
EP2412809B1 (en) 2009-03-24 2017-08-09 Kaneka Corporation Protein having affinity for immunoglobulin, and immunoglobulin-binding affinity ligand
HRP20160274T1 (hr) * 2009-04-03 2016-04-08 University Of Chicago Pripravci i metode vezane za varijante proteina a (spa)
AU2011274367B2 (en) 2010-07-02 2015-04-23 The University Of Chicago Compositions and methods related to protein A (SpA) variants
SG10201604559TA (en) 2011-06-08 2016-07-28 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
US9556281B2 (en) * 2011-08-15 2017-01-31 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein A
WO2014179744A1 (en) * 2013-05-03 2014-11-06 The University Of Chicago Staphylococcus live cell vaccines
GB201506868D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
CA3139981A1 (en) 2019-05-14 2020-11-19 The University Of Chicago Methods and compositions comprising staphylococcus protein a (spa) variants
US12528882B2 (en) 2019-09-13 2026-01-20 The University Of Chicago Methods and compositions for treating staphylococcal infections
EP4762077A1 (en) * 2023-08-14 2026-06-24 Cytiva BioProcess R&D AB Vh3 binding separation matrix and methods for using the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8300693L (sv) * 1983-02-09 1984-08-10 Sven Lofdahl Sett att framstella och isolera proteiner och polypeptider samt en hybridvektor for detta
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US4879378A (en) 1989-03-30 1989-11-07 Union Carbide Chemicals And Plastics Company Inc. Polysiloxanes with pendant sterically hindered phenol moiety connected to the silicon atom via a carbonylyoxy-containing link
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5198531A (en) 1991-06-14 1993-03-30 Research Diagnostic Antibodies Polymeric resin for peptide synthesis
US5240680A (en) 1991-12-19 1993-08-31 Chiron Corporation Automated apparatus for use in peptide synthesis
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5891438A (en) * 1992-10-30 1999-04-06 The Regents Of The University Of California Method for stimulating production of variable region gene family restricted antibodies through B-cell superantigen vaccination
SE9400088D0 (sv) * 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
WO1997000271A1 (en) 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
US6031071A (en) 1996-01-24 2000-02-29 Biophage, Inc. Methods of generating novel peptides
US6447777B1 (en) * 1996-03-29 2002-09-10 David S. Terman Polymerized staphylococcal protein a for treatment of diseases
US6013763A (en) * 1996-06-04 2000-01-11 Genentech, Inc. Peptide variants of protein A

Also Published As

Publication number Publication date
EP2017343A2 (en) 2009-01-21
EP1181052A4 (en) 2004-08-11
JP2002544237A (ja) 2002-12-24
AU777005B2 (en) 2004-09-30
EP2017343A3 (en) 2009-01-28
WO2000069457A1 (en) 2000-11-23
US20060205016A1 (en) 2006-09-14
AU5019100A (en) 2000-12-05
EP1181052A1 (en) 2002-02-27

Similar Documents

Publication Publication Date Title
EP2017343A2 (en) Protein A based binding domains with desirable activities
Potter et al. Staphylococcal protein A simultaneously interacts with framework region 1, complementarity-determining region 2, and framework region 3 on human VH3-encoded Igs
JP5431920B2 (ja) 受容体チロシンキナーゼａｌｋの細胞外ドメインに結合する抗体
Roben et al. VH3 family antibodies bind domain D of staphylococcal protein A.
EP2989204B1 (en) Isolation of therapeutic target specific vnar domains to icosl
Silverman et al. A model B-cell superantigen and the immunobiology of B lymphocytes
KR102256152B1 (ko) Ｐｄ-1 항체, 이의 항원 결합 단편, 및 이의 의약 용도
RU2712251C1 (ru) Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения
Buonpane et al. Characterization of T cell receptors engineered for high affinity against toxic shock syndrome toxin-1
AU2007200937A1 (en) Antigenic polypeptides
KR100328112B1 (ko) 류마토이드관절염병원관련관절염성펩티드에대항하는면역보호유도에유용한백신조성물과방법
SK284879B6 (sk) Polypeptidy so schopnosťou tvorby väzbových štruktúr na antigén so špecificitou pre Rhesus D antigény, DNA kódujúce také polypeptidy, spôsob ich prípravy a použitie
US7163686B1 (en) Protein A based binding domains with desirable activities
CA2217776C (en) Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
Lucas et al. Variable region sequences of a protective human monoclonal antibody specific for the Haemophilus influenzae type b capsular polysaccharide
US20110245153A1 (en) Neutralizing Agents for Bacterial Toxins
HUT67654A (en) Method of producing antibodies to a restricted population of t-lymphocytes, antibodies and method of use
WO1995031984A1 (en) Method and reagents for the treatment of rheumatoid arthritis
US6613536B1 (en) Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
Silverman et al. B-cell superantigens: molecular and cellular implications
Michaelsen et al. Construction and functional activities of chimeric mouse-human immunoglobulin G and immunoglobulin M antibodies against the Neisseria meningitidis PorA P1. 7 and P1. 16 epitopes
Chen et al. Protection of IgE-mediated allergic sensitization by active immunization with IgE loops constrained in GFP protein scaffold
Silver-man B-Cell Superantigens: An Overview of Structural, Evolutionary, and Immunobiologic Considerations
Mazigi Molecular engineering of antibody and superantigen interactions
Berry Antibody gene markers and their relationship to the chlamydial major outer membrane protein (MOMP) immune response

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued